For health-tech vendors selling into the NHS
The NHS business case that gets a health-tech deal signed.
Your clinical lead is excited. The pilot went well. Then the deal goes quiet inside the trust. This is why that happens, what goes into an NHS business case finance will actually approve, and how to make the internal sale almost effortless for the one person carrying it.
The clinical lead is sold. Then the deal stalls.
Most health-tech vendors are good at the first part. You get a clinical lead genuinely excited about the product. The problem is what happens next. That champion now has to push the purchase through the trust, and the internal workload is enormous: build the business case, find the finance evidence, work out which budget it comes from, and line up every person who has to approve. They have a day job. The enthusiasm fades under the workload, and the deal dies of friction, not of a no.
The fix is not more product excitement. It is to do that internal lift for the champion, so the ask on them is small and the momentum they started with carries the deal all the way to signature.
What goes into an NHS business case finance will approve
A Director of Finance does not buy enthusiasm. They approve a case that answers five questions clearly. Most vendor decks answer none of them, which is exactly why the NHS business case is the part of the sale that stalls.
1. Which budget line does this reduce?
Not "efficiency" in the abstract. A specific line: agency and locum cover, staff time, readmissions, estates, drug spend. Build the case from the trust's own figures so it points at a real budget, not a vague benefit.
2. Is the saving cash-releasing or productivity?
Be explicit. A cash-releasing saving takes money out of a budget line and is what finance can act on. A productivity saving frees time or capacity and supports the case but is harder to bank. Conflating the two is the fastest way to lose credibility in the room.
3. Who owns the saving inside the trust?
Name the budget holder who will be accountable for the benefit. The case has to be addressed to a person, not a department. Knowing who owns it also tells your champion exactly who else has to be in the room.
4. How is it measured over twelve months?
State the baseline before go-live, the metric, and the review cadence, up front. Finance trusts a number it can check later far more than a number it has to take on faith.
5. What evidence would satisfy a CFO?
A board-ready case built from the trust's own numbers, cited to recognised benchmarks, expressed as cashable pound-value, in the format finance expects. That is the artifact that gets signed.
How Throughline lowers the ask on your champion
Throughline is the tool that does the internal lift. It builds the cashable, finance-ready business case from the buyer's own numbers, then hands your champion a ready-to-forward pack mapped to each person who has to approve, with a tailored note and document for each one. The clinical lead is already sold. Throughline means they do not have to become a finance analyst and a project manager to get the deal done. The internal sale is mostly built for them, so their momentum survives to the signature.
Where the business case fits in the wider NHS sale
The NHS business case is one stage of a long, multi-stakeholder sale. If you are building the whole motion, it connects to the rest of the work: health-tech marketing built for the NHS buying process, the sales enablement that arms every rep with the same finance-ready story, and fractional CMO leadership to hold it all together. When you want a number to work from, the pricing is public.